LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.  

Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs will present additional study results and share implications of the study. 

The webcast will be held in English and will offer attendees the opportunity to ask questions. Here is the link to join the webcast: 
https://access.creomediamanager.com/registration/5a1817e6-d829-4839-bbb7-67368c517927?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F5a1817e6-d829-4839-bbb7-67368c517927

A recording of the presentation will be available on Immunovia’s website following the webcast.

For further information, please contact

Jeff Borcherding, CEO

jeff.borcherding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.